Research team confirms safety of Alzheimer's drug Lecanemab

TOKYO -- More than 90 pct of patients receiving Lecanemab, an Alzheimer's drug, in hospitals across Japan have been able to continue treatment without strong side effects, a group of researchers in the country said.

Go to News Site